Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PLK4 | O00444 | 1/20 | 0.41 |
| ▸ | PAK4 | O96013 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31716910 | 0.74 | KMT2A (0.80) | ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL7887065 | 0.74 | SMN1; SMN2 (0.48) | ALDH1A1SMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL20213747 | 0.73 | GAA (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL7882599 | 0.73 | PDE9A (0.52) | ALDH1A1SMN1; SMN2KMT2AHTTGAA | |
| SCHEMBL7887026 | 0.71 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL7887063 | 0.70 | AR (0.49) | ALDH1A1SMN1; SMN2GAA | |
| SCHEMBL7883156 | 0.70 | PDE9A (0.49) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL4497867 | 0.69 | ALDH1A1 (0.57) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL16712554 | 0.69 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL403830 | 0.68 | PDE5A (0.67) | ALDH1A1SMN1; SMN2RAB9AKMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11091490-B2 | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors | MEDIZINISCHE UNIVERSITÄT INNSBRUCK (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20200247809-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2020-08-06 | — | — | US | disclosed |
| EP-3548488-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | Oncotyrol Center for Personalized Cancer Medicine GmbH (AT) | 2019-10-09 | — | — | EP | disclosed |
| WO-2018099952-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | ONCOTYROL CENTER FOR PERSONALIZED CANCER MEDICINE GMBH (AT) | 2018-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11091490-B2 | 3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones as cyclin dependent kinase inhibitors | CDK4, CDK2, CDK3 | ALDH1A1 1007/4885SMN1; SMN2 3668/4885NPC1 4689/4885 |
| US-20200247809-A1 | 3-AMINO-1,5-DIHYDRO-PYRAZOLO[3,4-D]PYRIMIDIN-4-ONES AS CYCLIN DEPENDENT KINASE INHIBITORS | CDK3, CDK4, CDK2 | ALDH1A1 1472/4885SMN1; SMN2 4078/4885NPC1 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.